FR2711670B1
(fr)
|
1993-10-22 |
1996-01-12 |
Pasteur Institut |
Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
|
US6995008B1
(en)
*
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
US6727230B1
(en)
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US5736524A
(en)
*
|
1994-11-14 |
1998-04-07 |
Merck & Co.,. Inc. |
Polynucleotide tuberculosis vaccine
|
FR2732895B1
(fr)
*
|
1995-04-11 |
1997-05-16 |
Pasteur Merieux Serums Vacc |
Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
|
US6290969B1
(en)
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6338852B1
(en)
|
1995-09-01 |
2002-01-15 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6592877B1
(en)
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US20020165183A1
(en)
*
|
1999-11-29 |
2002-11-07 |
Hans Herweijer |
Methods for genetic immunization
|
US20070021364A1
(en)
*
|
1995-12-13 |
2007-01-25 |
Hans Herweijer |
Methods for genetic immunization
|
ZA973642B
(en)
*
|
1996-04-26 |
1997-11-25 |
Merck & Co Inc |
DNA vaccine formulations.
|
US5846946A
(en)
*
|
1996-06-14 |
1998-12-08 |
Pasteur Merieux Serums Et Vaccins |
Compositions and methods for administering Borrelia DNA
|
FR2751225B1
(fr)
*
|
1996-07-19 |
1998-11-27 |
Rhone Merieux |
Formule de vaccin polynucleotidique aviaire
|
FR2751228B1
(fr)
*
|
1996-07-19 |
1998-11-20 |
Rhone Merieux |
Vaccin polynucleotidique bovin pour voie intradermique
|
WO1998012332A1
(en)
*
|
1996-09-17 |
1998-03-26 |
Chiron Corporation |
Compositions and methods for treating intracellular diseases
|
US6797276B1
(en)
*
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
US20060002959A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Government Of The United States |
Skin-sctive adjuvants for transcutaneous immuization
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
US5980898A
(en)
*
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
AU6148798A
(en)
*
|
1997-02-07 |
1998-08-26 |
Vanderbilt University |
Synthetic genes for recombinant mycobacterium proteins
|
US6261281B1
(en)
*
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
US20040258703A1
(en)
*
|
1997-11-14 |
2004-12-23 |
The Government Of The Us, As Represented By The Secretary Of The Army |
Skin-active adjuvants for transcutaneous immunization
|
EP1071377A1
(de)
*
|
1998-04-14 |
2001-01-31 |
Merck & Co., Inc. |
Nadellose verabreichung von polynukleotiden formationen
|
WO2000026248A2
(en)
*
|
1998-11-04 |
2000-05-11 |
Isis Innovation Limited |
Tuberculosis diagnostic test
|
US8197461B1
(en)
|
1998-12-04 |
2012-06-12 |
Durect Corporation |
Controlled release system for delivering therapeutic agents into the inner ear
|
US6465633B1
(en)
|
1998-12-24 |
2002-10-15 |
Corixa Corporation |
Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
|
US7022320B1
(en)
|
1999-02-09 |
2006-04-04 |
Powderject Vaccines, Inc. |
Mycobacterium tuberculosis immunization
|
JP4932086B2
(ja)
*
|
1999-04-08 |
2012-05-16 |
インターセル ユーエスエイ、インコーポレイテッド |
経皮的免疫のための乾燥製剤
|
US20040265285A1
(en)
*
|
1999-04-15 |
2004-12-30 |
Monash University |
Normalization of defective T cell responsiveness through manipulation of thymic regeneration
|
US20040259803A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Disease prevention by reactivation of the thymus
|
US20050020524A1
(en)
*
|
1999-04-15 |
2005-01-27 |
Monash University |
Hematopoietic stem cell gene therapy
|
US20070274946A1
(en)
*
|
1999-04-15 |
2007-11-29 |
Norwood Immunoloty, Ltd. |
Tolerance to Graft Prior to Thymic Reactivation
|
US20040258672A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Graft acceptance through manipulation of thymic regeneration
|
US20040241842A1
(en)
*
|
1999-04-15 |
2004-12-02 |
Monash University |
Stimulation of thymus for vaccination development
|
AUPR074500A0
(en)
*
|
2000-10-13 |
2000-11-09 |
Monash University |
Treatment of t cell disorders
|
DE60045005D1
(de)
*
|
1999-06-28 |
2010-11-04 |
Oklahoma Med Res Found |
Inhibitoren des memapsin 2 und ihre verwendung
|
US6514948B1
(en)
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
US20050100928A1
(en)
*
|
1999-09-16 |
2005-05-12 |
Zycos Inc., A Delaware Corporation |
Nucleic acids encoding polyepitope polypeptides
|
AU2400500A
(en)
*
|
1999-11-01 |
2001-05-14 |
Chiron Corporation |
Expression vectors, transfection systems, and method of use thereof
|
DE60043158D1
(de)
|
1999-11-18 |
2009-11-26 |
Pharmexa Inc |
Heteroklitische analoga von klasse-i epitopen
|
WO2001045639A2
(en)
*
|
1999-12-22 |
2001-06-28 |
The Ohio State University Research Foundation |
Methods for protecting against lethal infection with bacillus anthracis
|
FR2804028B1
(fr)
*
|
2000-01-21 |
2004-06-04 |
Merial Sas |
Vaccins adn ameliores pour animaux de rente
|
CA2398756A1
(en)
*
|
2000-01-31 |
2001-08-02 |
Eyal Raz |
Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
|
CA2399550A1
(en)
|
2000-02-23 |
2001-08-30 |
The Regents Of The University Of California |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
US20030130217A1
(en)
*
|
2000-02-23 |
2003-07-10 |
Eyal Raz |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
CA2407303A1
(en)
*
|
2000-04-28 |
2001-11-08 |
Genoveffa Franchini |
Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
|
US6590087B1
(en)
*
|
2000-05-25 |
2003-07-08 |
Johns Hopkins University |
whmD, an essential cell division gene from mycobacteria
|
AU2001271963A1
(en)
*
|
2000-07-10 |
2002-01-21 |
Colorado State University Research Foundation |
Mid-life vaccine and methods for boosting anti-mycobacterial immunity
|
ATE429643T1
(de)
|
2000-07-12 |
2009-05-15 |
Agensys Inc |
Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
|
PT1313850E
(pt)
|
2000-08-28 |
2008-11-18 |
Agensys Inc |
Ácido nucleico e proteína correspondente denominados 85p1b3 úteis no tratamento e na detecção de cancro
|
US20060088512A1
(en)
*
|
2001-10-15 |
2006-04-27 |
Monash University |
Treatment of T cell disorders
|
EP1911461B1
(de)
|
2000-10-19 |
2011-12-07 |
Epimmune Inc. |
HLA-Klasse-I- und -Klasse-II-bindende Peptide und ihre Verwendungen
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
WO2002064162A2
(en)
*
|
2001-02-13 |
2002-08-22 |
Government Of The United States, As Represented By The Secretary Of The Army |
Vaccine for transcutaneous immunization
|
US7491394B2
(en)
|
2001-02-15 |
2009-02-17 |
The Board Of Trustees Of The University Of Illinois |
Cytotoxic factors for modulating cell death
|
US6924358B2
(en)
|
2001-03-05 |
2005-08-02 |
Agensys, Inc. |
121P1F1: a tissue specific protein highly expressed in various cancers
|
US7271240B2
(en)
|
2001-03-14 |
2007-09-18 |
Agensys, Inc. |
125P5C8: a tissue specific protein highly expressed in various cancers
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
AU2002303247B2
(en)
*
|
2001-04-06 |
2005-03-24 |
Dana-Farber Cancer Institute |
Chemotherapeutic induction of Egr-1 promoter activity
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
WO2002083921A2
(en)
|
2001-04-10 |
2002-10-24 |
Agensys, Inc. |
Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
|
US7013940B2
(en)
*
|
2001-04-19 |
2006-03-21 |
Michelin Recherche Et Technique S.A. |
Device for attenuating cavity noise in a tire and wheel
|
WO2002095002A2
(en)
|
2001-05-22 |
2002-11-28 |
University Of Chicago |
N4 virion single-stranded dna dependent rna polymerase
|
AU2002326751A1
(en)
*
|
2001-08-13 |
2003-03-03 |
Ige Therapeutics, Inc. |
Immunoglobulin e vaccines and methods of use thereof
|
ES2537074T3
(es)
|
2001-09-06 |
2015-06-02 |
Agensys, Inc. |
Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
|
MXPA04003944A
(es)
|
2001-10-26 |
2004-07-08 |
Baylor College Medicine |
Una composicion y metodo para alterar la masa corporal fina y propiedades oseas en un sujeto.
|
EP1465654B1
(de)
*
|
2001-12-11 |
2015-02-25 |
Inovio Pharmaceuticals, Inc. |
Durch plasmid übertragene supplementierung zur behandlung chronisch kranker patienten
|
EP1470161A1
(de)
*
|
2002-01-18 |
2004-10-27 |
Inovio AS |
Bispezifische antikörper-dna-konstrukte für die intramuskuläre verabreichung
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US20030166282A1
(en)
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
US20050267025A1
(en)
*
|
2002-02-01 |
2005-12-01 |
Ho John L |
Compositions and methods for treatment of infectious and inflammatory diseases
|
WO2003063798A2
(en)
*
|
2002-02-01 |
2003-08-07 |
Cornell Research Foundation, Inc. |
Compositions and methods for treatment of infectious and inflammatory diseases
|
EP2213737B1
(de)
|
2002-02-01 |
2012-11-07 |
Life Technologies Corporation |
Doppelsträngige Oligonukleotide
|
EP2258712A3
(de)
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
|
AU2003218181A1
(en)
*
|
2002-03-15 |
2003-09-29 |
Multicell Immunotherapeutics, Inc. |
Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response
|
US20070037769A1
(en)
*
|
2003-03-14 |
2007-02-15 |
Multicell Immunotherapeutics, Inc. |
Compositions and methods to treat and control tumors by loading antigen presenting cells
|
US7078037B2
(en)
*
|
2002-04-19 |
2006-07-18 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections
|
US20060094006A1
(en)
*
|
2002-05-01 |
2006-05-04 |
Genoveffa Franchini |
Immunotherapy regimens in hiv-infected patients
|
US7563882B2
(en)
|
2002-06-10 |
2009-07-21 |
University Of Rochester |
Polynucleotides encoding antibodies that bind to the C35 polypeptide
|
US20090110702A1
(en)
*
|
2002-07-12 |
2009-04-30 |
The Johns Hopkins University |
Mesothelin Vaccines and Model Systems and Control of Tumors
|
CA2492160A1
(en)
*
|
2002-07-12 |
2004-01-22 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
US9200036B2
(en)
|
2002-07-12 |
2015-12-01 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
ATE497774T1
(de)
|
2002-07-15 |
2011-02-15 |
Univ Texas |
Screening kombinatorischer proteinbibliotheken mittels periplasmatischer expression
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
JP4796299B2
(ja)
|
2002-08-12 |
2011-10-19 |
ジェンネレックス インコーポレイティッド |
ポックスウイルスおよび癌に関する方法および組成物
|
WO2004016733A2
(en)
|
2002-08-16 |
2004-02-26 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
|
EP1556513B1
(de)
*
|
2002-10-21 |
2010-04-28 |
Eisai Inc. |
Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
|
AU2002352976B2
(en)
|
2002-11-27 |
2007-11-08 |
Agensys, Inc. |
Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
|
EP1903056A3
(de)
|
2002-12-10 |
2008-05-07 |
Idm Pharma, Inc. |
HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
|
CA2860151A1
(en)
|
2003-02-10 |
2004-08-26 |
Agensys, Inc. |
Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
|
US7262027B2
(en)
*
|
2003-03-14 |
2007-08-28 |
Medical College Of Ohio |
Polypeptide and DNA immunization against Coccidioides spp. infections
|
CA2520181A1
(en)
*
|
2003-03-26 |
2004-10-14 |
Astral Inc. |
Selected rna motifs to include cell death and/or apoptosis
|
TW200424214A
(en)
*
|
2003-04-21 |
2004-11-16 |
Advisys Inc |
Plasmid mediated GHRH supplementation for renal failures
|
WO2004098497A2
(en)
*
|
2003-04-28 |
2004-11-18 |
Genencor International, Inc. |
Cd4+ human papillomavirus (hpv) epitopes
|
PT1629088E
(pt)
|
2003-05-30 |
2012-04-10 |
Agensys Inc |
Variantes de antigénio de células estaminais de próstata (psca) e subsequências das mesmas
|
WO2004110482A1
(en)
*
|
2003-06-13 |
2004-12-23 |
Isis Innovation Limited |
Improved vaccines
|
EP2336768A1
(de)
|
2003-07-09 |
2011-06-22 |
Life Technologies Corporation |
Verfahren zum testen einer Protein-Protein-Wechselwirkung
|
US20070224615A1
(en)
*
|
2003-07-09 |
2007-09-27 |
Invitrogen Corporation |
Methods for assaying protein-protein interactions
|
AU2004271951B2
(en)
*
|
2003-09-05 |
2008-08-21 |
Genencor International, Inc. |
HPV CD8+ T-cell epitopes
|
US20080279812A1
(en)
*
|
2003-12-05 |
2008-11-13 |
Norwood Immunology, Ltd. |
Disease Prevention and Vaccination Prior to Thymic Reactivation
|
US8188244B2
(en)
*
|
2004-02-11 |
2012-05-29 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Carcinoembryonic antigen fusions and uses thereof
|
CA2559586A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving s-ship promoter regions
|
WO2005118864A2
(en)
|
2004-05-28 |
2005-12-15 |
Agensys, Inc. |
Antibodies and related molecules that bind to psca proteins
|
WO2006017279A2
(en)
*
|
2004-07-12 |
2006-02-16 |
Board Of Regents, The University Of Texas System |
Methods and compositions related to identifying protein-protein interactions
|
WO2006135382A2
(en)
|
2004-08-04 |
2006-12-21 |
Chemocentryx, Inc. |
Enzymatic activities in chemokine-mediated inflammation
|
DK2302055T3
(da)
|
2004-11-12 |
2014-10-13 |
Asuragen Inc |
Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
|
CN101090974B
(zh)
|
2004-11-16 |
2011-05-11 |
克鲁塞尔荷兰公司 |
包含重组病毒载体的多价疫苗
|
JP5461776B2
(ja)
*
|
2004-12-01 |
2014-04-02 |
エーラス グローバル ティービー ワクチン ファウンデーション |
マイコバクテリウムのエレクトロポレーションおよびマイコバクテリア中における抗原類の過剰発現
|
US20080254059A1
(en)
*
|
2005-02-11 |
2008-10-16 |
Bett Andrew J |
Adenovirus Serotype 26 Vectors, Nucleic Acid and Viruses Produced Thereby
|
JP4461179B2
(ja)
|
2005-02-25 |
2010-05-12 |
オンコセラピー・サイエンス株式会社 |
Ttk、urlc10、またはkoc1ポリペプチドを発現する肺癌に対するペプチドワクチン
|
DK2289533T3
(da)
|
2005-02-28 |
2013-12-02 |
Oncotherapy Science Inc |
Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
|
AU2006230563B8
(en)
|
2005-03-31 |
2010-06-17 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161P2F10B proteins
|
CN105012953B
(zh)
|
2005-07-25 |
2018-06-22 |
阿普泰沃研发有限责任公司 |
用cd37-特异性和cd20-特异性结合分子减少b-细胞
|
PT1910839T
(pt)
|
2005-07-27 |
2016-07-14 |
Oncotherapy Science Inc |
Gene tom34 relacionado com o cancro do cólon
|
CA2618508A1
(en)
*
|
2005-08-10 |
2007-02-22 |
Oklahoma Medical Research Foundation |
Truncated memapsin 2 for use for treating alzheimer's disease
|
KR20090004839A
(ko)
*
|
2005-09-07 |
2009-01-12 |
제네렉스, 인코포레이티드 |
Gm-csf를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
US7919258B2
(en)
*
|
2005-10-07 |
2011-04-05 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Rapid tuberculosis detection method
|
WO2008019162A2
(en)
|
2006-01-18 |
2008-02-14 |
University Of Chicago |
Compositions and methods related to staphylococcal bacterium proteins
|
EP2397852B1
(de)
|
2006-03-14 |
2013-12-04 |
Oregon Health and Science University |
Methoden zur Detektion einer Mycobakterium tuberculosis Infektion
|
GB0605474D0
(en)
*
|
2006-03-17 |
2006-04-26 |
Isis Innovation |
Clinical correlates
|
CA2654317A1
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
US20100055113A1
(en)
|
2006-07-27 |
2010-03-04 |
The University Of Maryland, Baltimore |
Cellular receptor for antiproliferative factor
|
CA2921048C
(en)
|
2006-09-15 |
2018-06-05 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
EP2476697B1
(de)
|
2006-10-17 |
2015-06-17 |
Oncotherapy Science, Inc. |
Peptidvakzinen für MPHOSPH1-Polypeptide exprimierenden Krebs
|
WO2008130437A2
(en)
*
|
2006-10-20 |
2008-10-30 |
Arizona Board Of Regents For And On Behalf Of Arizona State University |
Modified cyanobacteria
|
EP2102239B1
(de)
|
2006-11-30 |
2012-04-25 |
Research Development Foundation |
Verbesserte immunglobulin-bibliotheken
|
TWI494319B
(zh)
|
2007-02-21 |
2015-08-01 |
Oncotherapy Science Inc |
表現腫瘤相關抗原之癌症的胜肽疫苗
|
KR20080084528A
(ko)
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
TW201425333A
(zh)
|
2007-04-11 |
2014-07-01 |
Oncotherapy Science Inc |
腫瘤血管內皮標誌8胜肽及包含此胜肽之疫苗
|
CA2685675C
(en)
|
2007-05-01 |
2016-02-16 |
Research Development Foundation |
Immunoglobulin fc libraries
|
EP2167130A2
(de)
*
|
2007-07-06 |
2010-03-31 |
Trubion Pharmaceuticals, Inc. |
Bindungspeptide mit einer c-terminal-abgelegten spezifischen bindungsdomäne
|
KR101661946B1
(ko)
|
2007-08-31 |
2016-10-05 |
유니버시티 오브 시카고 |
스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
|
WO2009059011A2
(en)
|
2007-11-01 |
2009-05-07 |
Mayo Foundation For Medical Education And Research |
Hla-dr binding peptides and their uses
|
KR101588736B1
(ko)
|
2008-01-10 |
2016-01-26 |
리서치 디벨롭먼트 파운데이션 |
얼리키아 샤피엔시스에 대한 백신 및 진단제
|
AU2009207923A1
(en)
*
|
2008-01-23 |
2009-07-30 |
Rigshospitalet |
Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker YKL-40
|
MX356866B
(es)
|
2008-01-25 |
2018-06-18 |
Multivir Inc |
Biomarcadores p53.
|
ES2690554T3
(es)
|
2008-03-17 |
2018-11-21 |
The Scripps Research Institute |
Enfoques químicos y genéticos combinados para la generación de células madre pluripotentes inducidas
|
WO2009117134A2
(en)
*
|
2008-03-21 |
2009-09-24 |
National Institutes Of Health |
Aerosolized genetic vaccines and methods of use
|
EP2365003A1
(de)
*
|
2008-04-11 |
2011-09-14 |
Emergent Product Development Seattle, LLC |
CD37-Immuntherapeutikum und Kombination mit bifunktionellem Chemotherapeutikum davon
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
ES2741730T3
(es)
|
2008-05-19 |
2020-02-12 |
Advaxis Inc |
Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
JP2011522540A
(ja)
|
2008-06-04 |
2011-08-04 |
セルラー ダイナミクス インターナショナル, インコーポレイテッド |
非ウイルスアプローチを用いたiPS細胞の産生のための方法
|
EP2303316B1
(de)
*
|
2008-07-25 |
2013-04-24 |
Department of Biotechnology |
Konstruktion einer dna-chimäre zur entwicklung eines impfstoffs gegen leishmaniose und tuberkulose
|
CN107988261A
(zh)
|
2008-08-12 |
2018-05-04 |
细胞动力国际有限公司 |
产生ips细胞的方法
|
EP2328603A4
(de)
|
2008-08-18 |
2013-01-02 |
Univ Maryland |
Apf-derivate und verwendungsverfahren
|
EP2329044B1
(de)
|
2008-08-27 |
2016-05-18 |
Oncotherapy Science, Inc. |
Prmt1 für zielgene zur krebstherapie und -diagnose
|
BRPI0920041A2
(pt)
|
2008-10-06 |
2017-06-27 |
Univ Chicago |
composições e processos relacionados às proteínas eap, emp e/ou adsa bacterianas
|
JP2012506858A
(ja)
*
|
2008-10-23 |
2012-03-22 |
インターベット インターナショナル ベー. フェー. |
Lawsoniaintracellularisワクチン
|
TWI500932B
(zh)
|
2008-12-05 |
2015-09-21 |
Oncotherapy Science Inc |
Wdrpuh抗原決定位胜肽以及含此胜肽之疫苗
|
JP5651125B2
(ja)
|
2008-12-10 |
2015-01-07 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Mek阻害剤に対する耐性を付与するmek突然変異
|
EP2373784B1
(de)
|
2008-12-17 |
2017-10-25 |
The Scripps Research Institute |
Erzeugung und erhaltung von stammzellen
|
WO2010084488A1
(en)
|
2009-01-20 |
2010-07-29 |
Ramot At Tel-Aviv University Ltd. |
Mir-21 promoter driven targeted cancer therapy
|
TWI469791B
(zh)
|
2009-02-18 |
2015-01-21 |
Oncotherapy Science Inc |
Foxm1胜肽以及含此胜肽之疫苗
|
PL2408913T3
(pl)
|
2009-03-18 |
2017-07-31 |
Oncotherapy Science, Inc. |
Peptydy neil3 i zawierające je szczepionki
|
PL3281947T3
(pl)
|
2009-04-03 |
2020-07-27 |
The University Of Chicago |
Kompozycje i sposoby związane z wariantami białka A (SpA)
|
US8748381B2
(en)
|
2009-04-28 |
2014-06-10 |
Vanderbilt University |
Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
|
TWI507204B
(zh)
|
2009-05-26 |
2015-11-11 |
Oncotherapy Science Inc |
Cdc45l胜肽與含此胜肽之疫苗
|
KR101772860B1
(ko)
|
2009-06-05 |
2017-08-30 |
셀룰러 다이내믹스 인터내셔널, 인코포레이티드 |
T 세포 및 조혈 세포의 재프로그래밍
|
EP2470653A1
(de)
|
2009-08-26 |
2012-07-04 |
Research Development Foundation |
Verfahren zur erstellung von antikörperbibliotheken
|
KR101759888B1
(ko)
|
2009-09-14 |
2017-07-20 |
신라젠(주) |
종양 용해 백시니아 바이러스 병용 암 치료요법
|
CN103403026B
(zh)
|
2009-09-25 |
2016-05-11 |
美国政府(由卫生和人类服务部的部长所代表) |
Hiv-1中和抗体及其用途
|
AU2010300623A1
(en)
*
|
2009-09-30 |
2012-04-19 |
Saint Louis University |
Peptides for inducing heterosubtypic influenza T cell responses
|
BR112012008848A2
(pt)
|
2009-10-16 |
2019-09-24 |
Scripps Research Inst |
composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidas
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
EP2510088B1
(de)
|
2009-12-10 |
2016-10-05 |
Ottawa Hospital Research Institute |
Onkolytisches rhabdovirus
|
TW201136604A
(en)
|
2009-12-14 |
2011-11-01 |
Oncotherapy Science Inc |
TMEM22 peptides and vaccines including the same
|
US10080799B2
(en)
|
2010-02-12 |
2018-09-25 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions related to glycoprotein-immunoglobulin fusions
|
RU2571930C2
(ru)
|
2010-02-25 |
2015-12-27 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Мутации braf, обеспечивающие резистентность к ингибиторам braf
|
WO2011106705A2
(en)
|
2010-02-26 |
2011-09-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Dna-protein vaccination protocols
|
ES2631458T3
(es)
|
2010-03-04 |
2017-08-31 |
Interna Technologies B.V. |
Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
|
CA2792910A1
(en)
|
2010-03-11 |
2011-09-15 |
Yusuke Nakamura |
Hjurp peptides and vaccines including the same
|
JP5909482B2
(ja)
|
2010-03-31 |
2016-04-26 |
ザ スクリプス リサーチ インスティテュート |
細胞の再プログラム
|
TW201627003A
(zh)
|
2010-04-02 |
2016-08-01 |
腫瘤療法 科學股份有限公司 |
Ect2胜肽及含此胜肽之疫苗
|
JP2013523818A
(ja)
|
2010-04-05 |
2013-06-17 |
ザ・ユニバーシティー・オブ・シカゴ |
免疫反応のエンハンサーとしてのプロテインA(SpA)抗体に関連する組成物および方法
|
US9249195B2
(en)
|
2010-04-07 |
2016-02-02 |
Vanderbilt University |
Reovirus vaccines and methods of use therefor
|
WO2011133512A1
(en)
|
2010-04-19 |
2011-10-27 |
Research Development Foundation |
Rtef-1 variants and uses thereof
|
CA2799790A1
(en)
|
2010-06-09 |
2011-12-15 |
Dana-Farber Cancer Institute, Inc. |
A mek1 mutation conferring resistance to raf and mek inhibitors
|
US9376664B2
(en)
|
2010-06-14 |
2016-06-28 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
EP2582793B1
(de)
|
2010-06-15 |
2017-09-06 |
Cellular Dynamics International, Inc. |
Kompendium aus fertig gebauten stammzellmodellen zur abfrage biologischer reaktionen
|
EP2582794B2
(de)
|
2010-06-15 |
2024-04-24 |
FUJIFILM Cellular Dynamics, Inc. |
Erzeugung induzierter pluripotenter stammzellen aus kleinen volumina von peripherem blut
|
JP6002128B2
(ja)
|
2010-07-02 |
2016-10-05 |
ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago |
プロテインA(SpA)変種に関連する組成物および方法
|
NZ719520A
(en)
|
2010-07-06 |
2017-07-28 |
Int Tech Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
CA2804595C
(en)
|
2010-07-07 |
2018-11-13 |
Cellular Dynamics International, Inc. |
Endothelial cell production by programming
|
CA2806858C
(en)
|
2010-08-04 |
2021-06-15 |
Cellular Dynamics International, Inc. |
Reprogramming immortalized b cells
|
WO2012034067A1
(en)
|
2010-09-09 |
2012-03-15 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens
|
EP2618829B1
(de)
|
2010-09-22 |
2019-05-01 |
The Regents of the University of Colorado, a body corporate |
Smad7 zur behandlung von oraler mukositis oder psoriasis
|
JP2013541951A
(ja)
|
2010-10-01 |
2013-11-21 |
アメリカ合衆国 |
p53アイソフォームによる幹細胞機能の操作
|
CN107412756A
(zh)
|
2010-10-01 |
2017-12-01 |
宾夕法尼亚大学理事会 |
李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
|
WO2012087965A2
(en)
|
2010-12-22 |
2012-06-28 |
Fate Therapauetics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
|
US9919047B2
(en)
|
2011-01-04 |
2018-03-20 |
Sillajen, Inc. |
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
|
EP2474617A1
(de)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
MIR zur Behandlung von Neoangiogenese
|
RU2539035C2
(ru)
*
|
2011-01-13 |
2015-01-10 |
Амир Закиевич Максютов |
Профилактическая или терапевтическая полиэпитопная противотуберкулезная вакцинная конструкция, обеспечивающая индукцию клеточного иммунного ответа cd4+ или cd8+ т-лимфоцитов
|
EP2673299B1
(de)
|
2011-02-07 |
2017-05-10 |
Research Development Foundation |
Manipulierte immunglobulin-fc-polypeptide
|
EP2673358B1
(de)
|
2011-02-08 |
2019-01-09 |
FUJIFILM Cellular Dynamics, Inc. |
Herstellung blutbildender vorläuferzellen durch programmierung
|
CN103687611A
(zh)
|
2011-03-11 |
2014-03-26 |
阿德瓦希斯公司 |
基于李斯特菌属的佐剂
|
EP2694534B1
(de)
|
2011-04-08 |
2018-06-20 |
Evaxion Biotech ApS |
Proteine und nukleinsäuren zur verwendung für impstoffe gegen staphylococcus aureus
|
US8945588B2
(en)
|
2011-05-06 |
2015-02-03 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
|
US9822379B2
(en)
|
2011-05-19 |
2017-11-21 |
Fundación Pública Andaluza Progreso Y Salud |
Highly inducible dual-promoter lentiviral TET-ON system
|
EP2718427B1
(de)
|
2011-06-08 |
2017-01-11 |
Children's Hospital of Eastern Ontario Research Institute Inc. |
Zusammensetzungen zur behandlung von glioblastomen
|
JP2014520551A
(ja)
|
2011-07-11 |
2014-08-25 |
セルラー ダイナミクス インターナショナル, インコーポレイテッド |
細胞のリプログラミング方法およびゲノムの改変方法
|
JP6014904B2
(ja)
|
2011-07-29 |
2016-10-26 |
国立大学法人徳島大学 |
Erap1由来ペプチド及びその使用
|
DK2742133T3
(en)
|
2011-08-12 |
2017-12-04 |
Oncotherapy Science Inc |
MPHOSPH1 PEPTIDES AND VACCINES CONTAINING THESE
|
CN103906535B
(zh)
|
2011-08-15 |
2017-07-14 |
芝加哥大学 |
与葡萄球菌蛋白a的抗体相关的组合物和方法
|
WO2013026015A1
(en)
|
2011-08-18 |
2013-02-21 |
Dana-Farber Cancer Institute, Inc. |
Muc1 ligand traps for use in treating cancers
|
JP2013046596A
(ja)
*
|
2011-08-29 |
2013-03-07 |
Alpha-Nano-Medica Co Ltd |
新規な複合体、それを含有する医薬及び癌の治療方法
|
WO2013053899A1
(en)
|
2011-10-12 |
2013-04-18 |
Moeller Niels Iversen |
Peptides derived from campylobacter jejuni and their use in vaccination
|
SG2014012363A
(en)
|
2011-10-28 |
2014-09-26 |
Oncotherapy Science Inc |
Topk peptides and vaccines including the same
|
EP3369818B1
(de)
|
2011-12-22 |
2021-06-09 |
InteRNA Technologies B.V. |
Mirna zur behandlung von kopf-hals-karzinom
|
AU2013232291B8
(en)
|
2012-03-12 |
2016-07-21 |
Advaxis, Inc. |
Suppressor cell function inhibition following listeria vaccine treatment
|
DK2844275T3
(da)
|
2012-04-26 |
2020-07-13 |
Univ Chicago |
Staphylokok-koagulase-antigener og fremgangsmåder til anvendelse af disse
|
NZ702282A
(en)
|
2012-04-26 |
2016-07-29 |
Univ Chicago |
Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
|
US9561265B2
(en)
|
2012-07-10 |
2017-02-07 |
Oncotherapy Science, Inc. |
KIF20A epitope peptides for TH1 cells and vaccines containing the same
|
JP6255594B2
(ja)
|
2012-07-10 |
2018-01-10 |
オンコセラピー・サイエンス株式会社 |
Th1細胞のLY6Kエピトープペプチドおよびこれを含有するワクチン
|
JP6283861B2
(ja)
|
2012-09-11 |
2018-02-28 |
オンコセラピー・サイエンス株式会社 |
Ube2tペプチドおよびそれを含むワクチン
|
US9890216B2
(en)
|
2012-10-23 |
2018-02-13 |
Board Of Regents, The University Of Texas System |
Antibodies with engineered IgG Fc domains
|
EP2917348A1
(de)
|
2012-11-06 |
2015-09-16 |
InteRNA Technologies B.V. |
Kombination zur behandlung von erkrankungen oder zuständen im zusammenhang mit melanom oder behandlung von erkrankungen und zuständen im zusammenhang mit aktivierten b-raf-signalweg
|
US10125373B2
(en)
|
2013-01-22 |
2018-11-13 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Geminiviral vector for expression of rituximab
|
ES2904803T3
(es)
|
2013-02-20 |
2022-04-06 |
Regeneron Pharma |
Modificación genética de ratas
|
CA2901501C
(en)
|
2013-02-21 |
2023-03-07 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Vaccine composition
|
CA2901747A1
(en)
|
2013-02-22 |
2014-08-28 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
WO2014134144A1
(en)
|
2013-02-28 |
2014-09-04 |
The General Hospital Corporation |
Mirna profiling compositions and methods of use
|
EP2964774B1
(de)
|
2013-03-08 |
2020-05-06 |
The Regents of The University of Colorado, A Body Corporate |
Ptd-smad7-therapeutika
|
TWI658049B
(zh)
|
2013-03-12 |
2019-05-01 |
腫瘤療法 科學股份有限公司 |
Kntc2胜肽及含此胜肽之疫苗
|
ES2751423T3
(es)
*
|
2013-03-15 |
2020-03-31 |
Univ Geneve |
Vacunas antimicobacterianas
|
CN111905099A
(zh)
|
2013-03-27 |
2020-11-10 |
免疫疫苗技术有限公司 |
用于改善存活蛋白疫苗在癌症治疗中的功效的方法
|
RU2520078C1
(ru)
*
|
2013-04-25 |
2014-06-20 |
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) |
СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
|
AU2014317861B2
(en)
|
2013-09-09 |
2019-11-28 |
Figene, Llc |
Gene therapy for the regeneration of chondrocytes or cartilage type cells
|
US20170002064A1
(en)
|
2013-11-08 |
2017-01-05 |
The Board Of Regents Of The University Of Texas System |
Vh4 antibodies against gray matter neuron and astrocyte
|
WO2015070050A1
(en)
|
2013-11-08 |
2015-05-14 |
Baylor Research Institute |
Nuclear loclization of glp-1 stimulates myocardial regeneration and reverses heart failure
|
WO2015082536A1
(en)
|
2013-12-03 |
2015-06-11 |
Evaxion Biotech Aps |
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
|
CN106132992B
(zh)
|
2014-01-29 |
2020-08-07 |
达娜-法勃肿瘤研究所公司 |
针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
|
WO2015123561A2
(en)
|
2014-02-14 |
2015-08-20 |
University Of Utah Research Foundation |
Methods and compositions for inhibiting retinopathy of prematurity
|
CA2940765A1
(en)
|
2014-02-25 |
2015-09-03 |
Research Development Foundation |
Sty peptides for inhibition of angiogenesis
|
EP3114214B1
(de)
|
2014-03-04 |
2023-11-01 |
Fate Therapeutics, Inc. |
Verbesserte neuprogrammierungsverfahren und zellkulturplattformen
|
WO2015164228A1
(en)
|
2014-04-21 |
2015-10-29 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
KR20170040315A
(ko)
|
2014-08-04 |
2017-04-12 |
온코세라피 사이언스 가부시키가이샤 |
Cdca1-유래 펩티드 및 이를 포함하는 백신
|
KR102489834B1
(ko)
|
2014-08-04 |
2023-01-19 |
온코세라피 사이언스 가부시키가이샤 |
Koc1-유래 펩티드 및 이를 포함하는 백신
|
KR20170030649A
(ko)
|
2014-08-04 |
2017-03-17 |
온코세라피 사이언스 가부시키가이샤 |
Urlc10-유래 펩티드 및 이를 포함하는 백신
|
WO2016025510A1
(en)
|
2014-08-12 |
2016-02-18 |
Rappolee Daniel A |
Systems and methods to detect stem cell stress and uses thereof
|
WO2016075305A2
(en)
|
2014-11-13 |
2016-05-19 |
Evaxion Biotech Aps |
Peptides derived from acinetobacter baumannii and their use in vaccination
|
JP2018509384A
(ja)
|
2015-01-06 |
2018-04-05 |
イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. |
リピドa模倣体、調製方法、及びその使用
|
EP4279080A3
(de)
|
2015-01-12 |
2024-02-21 |
Evaxion Biotech A/S |
Behandlung und prophylaxe von k.-pneumoniae-infektionen
|
US20180002656A1
(en)
|
2015-01-28 |
2018-01-04 |
Sabic Global Technologies B.V. |
Methods and compositions for high-efficiency production of biofuel and/or biomass
|
AU2016219511B2
(en)
|
2015-02-09 |
2020-11-12 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides displaying improved complement activation
|
EP3259346A4
(de)
|
2015-02-20 |
2018-07-11 |
Baylor College of Medicine |
P63-inaktivierung zur behandlung von herzinsuffizienz
|
WO2016183420A1
(en)
|
2015-05-13 |
2016-11-17 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for inducing an immune response using conserved element constructs
|
WO2016196366A1
(en)
|
2015-05-29 |
2016-12-08 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Extension of replicative lifespan in diseases of premature aging using p53 isoforms
|
EP4116316A1
(de)
|
2015-07-04 |
2023-01-11 |
Evaxion Biotech A/S |
Proteine und nukleinsäuren, die in impfstoffen gegen pseudomonas aeruginosa nützlich sind
|
WO2017040380A2
(en)
|
2015-08-28 |
2017-03-09 |
Research Development Foundation |
Engineered antibody fc variants
|
EA201890613A1
(ru)
|
2015-09-21 |
2018-10-31 |
Аптево Рисёрч Энд Девелопмент Ллс |
Полипептиды, связывающие cd3
|
BR112018005581A2
(pt)
|
2015-10-08 |
2018-10-16 |
Oncotherapy Science, Inc. |
peptídeo derivado de foxm1 e vacina incluindo o mesmo
|
CN117737124A
(zh)
|
2015-10-16 |
2024-03-22 |
菲特治疗公司 |
用于诱导和维护基态多能性的平台
|
CA3002157A1
(en)
|
2015-10-20 |
2017-04-27 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for directed differentiation of pluripotent stem cells to immune cells
|
WO2017075389A1
(en)
|
2015-10-30 |
2017-05-04 |
The Regents Of The Universtiy Of California |
Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
|
SI3370733T1
(sl)
|
2015-11-02 |
2021-11-30 |
Board Of Regents The University Of Texas System |
Postopek za aktivacijo CD40 in blokada imunske nadzorne točke
|
EP3371221A2
(de)
|
2015-11-07 |
2018-09-12 |
MultiVir Inc. |
Verfahren und zusammensetzungen mit tumorsuppressorgentherapie und immuncheckpoint-blockade zur behandlung von krebs
|
WO2017083296A1
(en)
|
2015-11-09 |
2017-05-18 |
The Children's Hospital Of Philadelphia |
Glypican 2 as a cancer marker and therapeutic target
|
WO2017144523A1
(en)
|
2016-02-22 |
2017-08-31 |
Evaxion Biotech Aps |
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
|
US20190177391A1
(en)
|
2016-03-31 |
2019-06-13 |
Baylor Research Institute |
Angiopoietin-like protein 8 (angptl8)
|
WO2017216384A1
(en)
|
2016-06-17 |
2017-12-21 |
Evaxion Biotech Aps |
Vaccination targeting ichthyophthirius multifiliis
|
EP3474889A4
(de)
*
|
2016-06-22 |
2020-04-29 |
International AIDS Vaccine Initiative, Inc. |
Rekombinante cytomegalovirus-vektoren als impfstoffe gegen tuberkulose
|
WO2017220787A1
(en)
|
2016-06-24 |
2017-12-28 |
Evaxion Biotech Aps |
Vaccines against aearomonas salmonicida infection
|
CA3029582A1
(en)
|
2016-07-01 |
2018-01-04 |
Research Development Foundation |
Elimination of proliferating cells from stem cell-derived grafts
|
EP3487872A1
(de)
|
2016-07-22 |
2019-05-29 |
Evaxion Biotech ApS |
Chimäre proteine zur immunitätsinduktion gegen infektionen mit s. aureus
|
US9963498B2
(en)
|
2016-08-18 |
2018-05-08 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
|
KR102598351B1
(ko)
|
2016-10-05 |
2023-11-08 |
후지필름 셀룰러 다이내믹스, 인코포레이티드 |
만능 줄기 세포를 hla 동형 접합 면역 세포로 직접 분화시키기 위한 방법
|
WO2018067826A1
(en)
|
2016-10-05 |
2018-04-12 |
Cellular Dynamics International, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
WO2018127545A1
(en)
|
2017-01-05 |
2018-07-12 |
Evaxion Biotech Aps |
Vaccines targeting pseudomonas aeruginosa
|
EP4083063A3
(de)
|
2017-04-18 |
2023-01-04 |
FUJIFILM Cellular Dynamics, Inc. |
Antigenspezifische immuneffektorzellen
|
JP2021501594A
(ja)
|
2017-11-03 |
2021-01-21 |
インテアールエヌエー テクノロジーズ ビー.ヴイ.InteRNA Technologies B.V. |
ニューロンの欠損に関連する状態及び/又は疾患を処置及び/又は診断するため、或いはニューロンの再生/発生のための、miRNA分子、等価物、アンタゴミル、又はそれらの供給源
|
US11612618B2
(en)
|
2017-11-14 |
2023-03-28 |
Henry Ford Health System |
Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury
|
EP4137578A1
(de)
|
2018-01-05 |
2023-02-22 |
Ottawa Hospital Research Institute |
Modifizierte vaccinia-vektoren
|
WO2019145399A1
(en)
|
2018-01-24 |
2019-08-01 |
Evaxion Biotech Aps |
Vaccines for prophylaxis of s. aureus infections
|
WO2020036635A2
(en)
|
2018-03-19 |
2020-02-20 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
|
CN112105731A
(zh)
|
2018-03-30 |
2020-12-18 |
日内瓦大学 |
微小rna表达构建体及其用途
|
TW202023581A
(zh)
|
2018-08-02 |
2020-07-01 |
日商腫瘤療法 科學股份有限公司 |
來自cdca1的胜肽及含有此的疫苗
|
SG11202102058UA
(en)
|
2018-08-30 |
2021-03-30 |
Tenaya Therapeutics Inc |
Cardiac cell reprogramming with myocardin and ascl1
|
WO2020069313A2
(en)
|
2018-09-28 |
2020-04-02 |
Henry Ford Health System |
Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
|
WO2020083904A1
(en)
|
2018-10-22 |
2020-04-30 |
Evaxion Biotech Aps |
Vaccines targeting m. catharrhalis
|
JPWO2020111167A1
(ja)
|
2018-11-30 |
2021-10-28 |
国立大学法人徳島大学 |
Big3−phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬
|
WO2020171889A1
(en)
|
2019-02-19 |
2020-08-27 |
University Of Rochester |
Blocking lipid accumulation or inflammation in thyroid eye disease
|
US20220143168A1
(en)
|
2019-02-27 |
2022-05-12 |
Evaxion Biotech A/S |
Vaccines targeting H. influenzae
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
US20220257653A1
(en)
|
2019-07-19 |
2022-08-18 |
The Children's Hospital Of Philadelphia |
Chimeric antigen receptors containing glypican 2 binding domains
|
CN115175680A
(zh)
|
2019-10-18 |
2022-10-11 |
加利福尼亚大学董事会 |
Plxdc激活剂及其用于治疗血管病症的用途
|
KR102237349B1
(ko)
|
2019-10-23 |
2021-04-07 |
한국과학기술연구원 |
니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
WO2021140123A1
(en)
|
2020-01-06 |
2021-07-15 |
Evaxion Biotech Aps |
Vaccines targeting neisseria gonorrhoeae
|
EP4114421A1
(de)
|
2020-03-02 |
2023-01-11 |
Tenaya Therapeutics, Inc. |
Genvektorsteuerung durch kardiomyozyten-exprimierte mikrornas
|
JP2023520359A
(ja)
|
2020-03-25 |
2023-05-17 |
エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム |
放射性核種イメージングのためのレポーター系
|
WO2021240240A1
(en)
|
2020-05-27 |
2021-12-02 |
Antion Biosciences Sa |
Adapter molecules to re-direct car t cells to an antigen of interest
|
MX2022015002A
(es)
|
2020-05-29 |
2023-03-03 |
Fujifilm Cellular Dynamics Inc |
Bicapa del epitelio pigmentario de la retina y fotorreceptores y uso de los mismos.
|
WO2021243256A1
(en)
|
2020-05-29 |
2021-12-02 |
FUJIFILM Cellular Dynamics, Inc. |
Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
|
WO2022053130A1
(en)
|
2020-09-09 |
2022-03-17 |
Sid Alex Group, S.R.O. |
Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
|
CA3202849A1
(en)
|
2021-02-09 |
2022-08-18 |
University Of Houston System |
Oncolytic virus for systemic delivery and enhanced anti-tumor activities
|
WO2022175815A1
(en)
|
2021-02-19 |
2022-08-25 |
Pfizer Inc. |
Methods of protecting rna
|
CA3216719A1
(en)
|
2021-05-03 |
2022-11-10 |
Astellas Institute For Regenerative Medicine |
Methods of generating mature corneal endothelial cells
|
BR112023022181A2
(pt)
|
2021-05-07 |
2024-02-06 |
Astellas Inst For Regenerative Medicine |
Métodos de geração de hepatócitos maduros
|
CN117881777A
(zh)
|
2021-05-26 |
2024-04-12 |
富士胶片细胞动力公司 |
防止多能干细胞中基因快速沉默的方法
|
CA3224564A1
(en)
|
2021-07-05 |
2023-01-12 |
Andreas Holm MATTSSON |
Vaccines targeting neisseria gonorrhoeae
|
WO2023089556A1
(en)
|
2021-11-22 |
2023-05-25 |
Pfizer Inc. |
Reducing risk of antigen mimicry in immunogenic medicaments
|
WO2023144779A1
(en)
|
2022-01-28 |
2023-08-03 |
Pfizer Inc. |
Coronavirus antigen variants
|
US20230295661A1
(en)
|
2022-03-16 |
2023-09-21 |
University Of Houston System |
Persistent hsv gene delivery system
|
GB202205265D0
(en)
|
2022-04-11 |
2022-05-25 |
Mogrify Ltd |
Cell conversion
|
WO2023213393A1
(en)
|
2022-05-04 |
2023-11-09 |
Evaxion Biotech A/S |
Staphylococcal protein variants and truncates
|
GB202206507D0
(en)
|
2022-05-04 |
2022-06-15 |
Antion Biosciences Sa |
Expression construct
|
US20240010742A1
(en)
|
2022-06-10 |
2024-01-11 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|
US20240003871A1
(en)
|
2022-06-29 |
2024-01-04 |
FUJIFILM Cellular Dynamics, Inc. |
Ipsc-derived astrocytes and methods of use thereof
|